Decheng Capital
Venture capitalActively deployingMenlo Park · Seed–Growth · 19 people tracked
Also known as Decheng Capital China Life Sciences USD · Decheng Capital Global Life Sciences · DECHENG CAPITAL LLC
Find your way into Decheng Capital
1,341 people in our graph share verified history with the Decheng Capital team — schools, employers, funds. One of them is your warm intro.
Investment thesis
Decheng Capital focuses on the healthcare and life science sectors, backing early-stage life science companies with breakthrough technologies as well as growth-stage healthcare companies that have an established market presence. The firm views the rapid growth of the healthcare industry and advances in life science research as a historic opportunity, and combines capital with strategic support to help build successful companies globally. It draws on a team with complementary expertise and backing from prominent limited partners to create value for both investors and entrepreneurs.
Source: firm website, verified Sep 15, 2026.
Team · 19 people
from the firm's website & curated & public directories
What they invest in
from 63 of 103 portfolio companiesBiotech ×50Healthtech ×40Medical Devices ×29Deep Tech ×13AI & Machine Learning ×12Digital Health ×9Advanced Manufacturing ×5Hardware ×5
HQs:United States×38China×7Canada×1Hong Kong×1
Who they back
founder profiles across 21 portfolio companiesFounding team size:solo founder×122 founders×63 founders×14+ founders×2
Where their founders studiedfrom 23 founders with education data
Harvard University ×3University of California, Berkeley ×3Imperial College London ×2Princeton University ×2The Johns Hopkins University ×2
What their founders studiedfrom 22 founders with field-of-study data
Life Sciences ×10Engineering ×4Physics ×4Chemistry ×3Business & Management ×2Medicine ×2
Where their founders worked beforefrom 24 founders with career history
Stanford University ×3Affymetrix ×2Harvard Medical School ×2Synthego ×2
14 founders hold a PhD · 2 hold an MBA (of 23 with degree data)
Investments · 103 tracked
founders shown can be your intro pathBy year:2026 · 32025 · 12024 · 32023 · 22022 · 12021 · 32020 · 52019 · 22018 · 12015 · 12012 · 123 dated
Aardvark Therapeutics is a clinical-stage biopharmaceutical company developing small-molecule drugs that inhibit hunger to treat metabolic diseases.
BiotechHealthtechLongevitySan Diego, US
Tien Lee(Founder & Chief Executive Officer)inZachary Hornby(Director)Jerel Banks(Director)Henry Ji(Director)Bob Shin(Director)
BoardJeffrey Chi(Director)
Co-investorsVickers Venture PartnersLG Technology VenturesPremier Partners
GRAIL develops the Galleri blood test for multi-cancer early detection using next-generation sequencing and machine learning to screen for multiple deadly cancer types before symptoms appear.
AI & Machine LearningBiotechHealthtechMedical DevicesMenlo Park, US
Jeffrey T. Huber(Director)Joshua Ofman, MD, MSHS(Chief Executive Officer)inAaron Freidin(Executive Officer)inJosh Ofman(Executive Officer)inRobert Ragusa(Executive Officer, Director)Jennifer Cook(Executive Officer, Director)in
Board seatMin Cui· per SEC Form D
Co-investorsAmino CapitalARCH Venture PartnersBezos ExpeditionsBluebird VenturesDentsu VenturesFelicis Ventures+8 more
-2.png)
Aadi Bioscience develops therapies targeting mTOR-driven diseases using precision medicine and albumin-bound nanoparticle technology, applying genomic profiling to identify patients most likely to benefit from mTOR inhibition.
BiotechHealthtechMorristown, US
Scott Giacobello(Executive Officer)inBryan Ball(Executive Officer)Dave Lennon(Executive Officer, Director)inDavid Dornan(Executive Officer)James Murphy(Executive Officer)Stephen Pakola(Executive Officer)
Co-investors3B Future Health FundAlly Bridge GroupVivo CapitalAvoro VenturesOrbiMed
Adaptive Biotechnologies applies the genetics of the adaptive immune system to diagnostics and therapeutics, translating immune-system data into clinical insights for clinicians and biopharma companies.
AI & Machine LearningBiotechDigital HealthHealthtechMedical DevicesSeattle, US
Chad Robins(Executive Officer, Director)inHarlan Robins(Executive Officer)inKathleen Determann(Executive Officer)inDean Schorno(Executive Officer)inChris Carlson(Executive Officer)Kyle Piskel(Chief Financial Officer)in
Co-investorsFMG CapitalForesite CapitalKhosla VenturesOrbiMed
CG Oncology develops an investigational oncolytic immunotherapy for urologic cancer patients, specifically targeting BCG-unresponsive non-muscle invasive bladder cancer.
BiotechHealthtechMedical Devices
Arthur Kuan(Chairman and Chief Executive Officer)in
Co-investorsForesite CapitalLongitude CapitalPalm Drive CapitalRA CapitalTCG CrossoverACORN BIOVENTURES+2 more
Health Catalyst provides a data platform, analytics applications, and AI-powered insights that help healthcare organizations improve clinical, financial, and operational performance.
AI & Machine LearningData & InfrastructureDigital Health
Benjamin Albert(Chief Executive Officer and Director)Jason Alger(Chief Financial Officer)inLinda Llewelyn(Chief People Officer)in
Co-investorsEPIC VENTURESFifty YearsKaiser Permanente VenturesNorwest Venture PartnersOSF VenturesTenaya Capital+2 more
Nuvation Bio is a global oncology company that develops novel cancer therapies through its own drug discovery programs and business development, serving cancer patients.
BiotechHealthtechNew York, US
David Hung(Founder)inDavid Hung, M.D.(Executive Officer, Director)inDavid Hanley(Chief Technical Operations Officer)inGary Hattersley(Chief Scientific Officer)inStacy Markel(Chief People Officer)inPhilippe Sauvage(Chief Financial Officer)in
Co-investorsAisling CapitalEcoR1 CapitalVertex Ventures ChinaOmega Funds
SCYNEXIS develops fungerp-based antifungal therapies, including SCY-247, for treating and preventing severe, progressive, and often fatal fungal diseases and antimicrobial-resistant infections.
BiotechDurham, US
Yves J. Ribeill(Executive Officer, Director)inCharles F. Osborne, Jr.(Executive Officer)Brian Schwab(Executive Officer)inDavid Angulo(Chief Executive Officer, President and Director)in
BoardLaurent Arthaud(Director)Mounia Chaoui(Director)
Co-investorsForesite CapitalDeerfield Management CompanyRA Capital
Upstream Bio is a biotechnology company that sponsors clinical trials to develop products under investigation.
BiotechHealthtechWaltham, US
Rand Sutherland(Chief Executive Officer)inAllison Ambrose(General Counsel)inAaron Deykin(Chief Medical Officer & Head of R&D)inMike Gray(Chief Financial Officer and Chief Operating Officer)Adam Houghton(Chief Business Officer)inStacy Price(Chief Technology Officer)in
Co-investorsOrbiMedAccess IndustriesAccess BiotechnologyBain Capital Life SciencesSamsara BioCapitalTCG Crossover+2 more
Imviva is a clinical-stage biotechnology company developing allogeneic CAR-T cell therapies for oncology and autoimmune diseases.
BiotechDeep TechHealthtechMedical Devices
Jiangtao Ren(Chief Scientific Officer)Lu Han(Chief Executive Officer)Yajin Ni(Chief Technology Officer)Jan Davidson(Chief Medical Officer)
Co-investorsGL VenturesHillhouse CapitalShenzhen Capital Group
Cellares develops automated manufacturing systems and technology platforms to accelerate the production and commercialization of cell therapies.
Advanced ManufacturingBiotechMedical DevicesSouth San Francisco, US
Fabian Gerlinghaus(Co-Founder and Chief Executive Officer)inOmar Kurdi(Co-Founder and President)in
BoardJustin Butler(Director)inVictor Tong(Director)in
Co-investors8VCEcoR1 CapitalIntuitive VenturesKoch Disruptive TechnologiesBaillie GiffordBlackRock+4 more
Solve Therapeutics is a clinical-stage oncology biotech developing antibody-drug conjugates (ADCs) and radiopharmaceuticals for solid tumors, built around its CloakLink hydrophilic cleavable linker platform and an integrated diagnostic for patient selection.
BiotechDeep TechHealthtech
David Johnson(Chief Executive Officer)Clayton Knox(President)Katti Jessen(SVP, Translational Sciences)Yakov Kogan(Head of Operations)Brian Lannutti(Research & Development Leadership)Langdon Miller(Clinical Development Leadership)
Co-investorsMatrix Capital ManagementYosemiteB Capital GroupB4 Capital
.jpeg){kind=logo}
A clinical-stage biotechnology company developing allogeneic CAR-T cell therapies for oncology and autoimmune diseases, targeting off-the-shelf and scalable treatments to improve patient access.
BiotechHealthtechMedical Devices
Lu Han(Chief Executive Officer)Jiangtao Ren(Chief Scientific Officer)Yajin Ni(Chief Technology Officer)
Co-investors7G BioVentures
Lynk Pharma develops pharmaceutical products for rheumatoid arthritis and ankylosing spondylitis, with selective licensing arrangements for regional commercialization.
AI & Machine LearningBiotechDeep TechHealthtechMedical DevicesHangzhou, CN
Zhao-Kui (ZK) Wan(Founder, Chairman of Board & CEO)Michael Vazquez(Co-founder & Executive Vice President)inJun Wang(Co-founder & CSO)inYan Chen(Co-founder & COO)in
Co-investorsLAVLilly Asia Ventures
AI & Machine LearningBiotechDigital HealthHealthtech
Co-investorsSamsara BioCapitalvenBio PartnersAccess IndustriesKleiner Perkins
Adela develops blood-based tests for cancer detection using epigenetics and liquid biopsy technology, aimed at helping patients and clinicians detect and act on cancer earlier.
BiotechDigital HealthHealthtechMedical DevicesFoster City, US
Daniel Diniz De Carvalho(Executive Officer, Promoter)Scott Bratman(Executive Officer, Director)inAnne-Renee Hartman(Founder)inAlan Williams(Executive Officer)inLisa Alderson(Executive Officer, Director)inPriscilla Huang(Executive Officer)in
Co-investorsF-Prime CapitalOrbiMedDeerfield Management CompanyMenlo Ventures
AK Medical is a company providing investor and corporate information, headquartered in Beijing with a principal place of business in Hong Kong.
Advanced ManufacturingHardwareHealthtechMedical DevicesBeijing, CN
Co-investorsOrbiMed
A biopharmaceutical company (Ipsen, following its acquisition of Albireo Pharma) developing and commercializing medicines in oncology, rare diseases, and neuroscience for patients with high unmet medical needs.
BiotechHealthtech
Co-investorsHEALTHCARE ROYALTY PARTNERS
BiotechSeattle, US
Mitchell Gold(Executive Chairman and Chief Executive Officer)inMichael Kornacker(Executive Officer, Director)inRyan Swanson(Executive Officer, Director)inDavid Miller(Executive Officer, Director)inJames Paul Rickey(Senior Vice President and Chief Financial Officer)Mark James Litton(President and Chief Operating Officer)
Co-investorsFrazier Life SciencesBiotechnology Value FundOrbiMed
Biopharma, acquired by Nuvation Bio (葆元医药)
Co-investorsCenova CapitalVertex Ventures China
Antengene is a biopharmaceutical company that develops therapies for cancer, with a pipeline focused on hematologic malignancies and solid tumors including Claudin 18.2, CD73, PD-L1/4-1BB bispecific, and CD24-targeting candidates.
BiotechHealthtech
Co-investorsQiming Venture PartnersBoyu Capital
Arcus Biosciences develops combination cancer therapies, producing small molecules and antibodies designed to be combined and advanced from Phase 1 studies through commercialization.
Biotech
Juan Jaen(Founder)in
Co-investorsAisling CapitalDroia VenturesEcoR1 CapitalForesite CapitalSLVCSofinnova Ventures+2 more
Ark Biosciences is a biopharmaceutical company developing small molecule drugs for infectious diseases, respiratory conditions, neuropsychiatric disorders, and rare diseases.
BiotechDigital HealthHealthtechMedical DevicesShanghai, CN
Co-investorsYuanBio Venture CapitalQiming Venture Partners
Beyond Spring Pharmaceuticals develops Plinabulin, a brain-penetrant immune modulator that activates dendritic cells through a differentiated tubulin-binding mechanism, intended to enhance antigen presentation and T cell activation for select tumor types.
BiotechHealthtechMedical Devices
Co-investorsSangel Capital
Clint Sever(Founder)in
Co-investorsACME CapitalDarwin CapitalDentsu VenturesForesite CapitalPrime PartnersCAVU Consumer Partners+1 more
San Diego protein-sequencing company behind the ProteoCode platform; ceased operations in late 2025.
Co-investorsARCH Venture PartnersAlexandriaDeerfield Management CompanyGV (Google Ventures)Nan Fung Life SciencesNorthpond Ventures
Epimab Biotherapeutics is a clinical-stage biopharmaceutical company specializing in the development of bispecific antibodies using proprietary technology platforms including FIT-Ig® and MAT-Fab.
BiotechHealthtechMedical DevicesShanghai, CN
Wu Chenbing(Founder/Expert)
Co-investorsShangBay Capital LLCTCG Labs3E Bioventures CapitalSherpa Healthcare Partners
Firefly Bio develops antibody-drug conjugates (ADCs) that use novel classes of payloads, drawing on a research team experienced in ADC discovery and development.
BiotechHealthtechMedical Devices
Scott Hirsch(CEO)inDan Kaplan(CSO)
Co-investorsMPM BioImpact
BiotechRedwood City, US
Hesaam Esfandyarpour(Executive Officer, Director)inFred Nazem(Director)Frank Witney(Director)Rakesh Sachdev(Director)Hamid Moghadam(Director)Laurent Bellon(Executive Officer)
Co-investorsIPV Capital
Grit Bio develops nine core technology platforms for cell therapy manufacturing and development, spanning TIL expansion, viral vector production, immunological target discovery, and LNP delivery systems for therapeutic applications.
AI & Machine LearningBiotechDeep TechDigital HealthHealthtechMedical DevicesBeijing, CN
刘雅容(Founder, Chairman & Chief Executive Officer)
Co-investorsB Capital GroupB4 Capital
Harton Therapeutics offers a GMP-ready platform for advanced 3D cell manufacturing, using a perfusion-based single-use cartridge system with automated process control to produce human cells at scale.
Advanced ManufacturingBiotechMedical Devices
Humi was a Canadian HR, payroll, and benefits software platform designed for small and medium-sized businesses in Canada.
AI & Machine LearningEnterprise SoftwareFintechHR TechSaaSToronto, CA
Kevin Kliman(Founder/CEO)inMatt Loszak(Founder/CTO)inDrew MillingtoninSimon Bourgeois(Founder)in
Co-investors500 Global7BC Venture CapitalAmplify.LAChartline Capital PartnersFundersClubGarage Capital+5 more
Hummingbird Bioscience is a precision biotherapeutics company developing a pipeline of novel targeted therapies for cancer, using proprietary drug discovery technologies and platforms.
AI & Machine LearningBiotechDeep TechHealthtech
Piers Ingram(Chief Executive Officer, Co-Founder, Executive Director)inJerome Boyd-Kirkup(Chief Scientific Officer, Co-Founder)inKonrad Paszkiewicz(Chief Technology Officer)inKwek Kon Yew(Chief Medical Officer)Dipti Thakkar(Chief Operating Officer)in
Co-investorsAltium CapitalClavystBioDroia VenturesFrazier Life SciencesKiwoom InvestmentMuirwoods Ventures+5 more
Incyte is a biopharmaceutical company that develops and commercializes medicines for oncology, hematology, dermatology, and other therapeutic areas.
BiotechHealthtechMedical DevicesWilmington, US
Bill Meury(Chief Executive Officer)inPablo J. Cagnoni(President, Incyte and Global Head of R&D)in
Insight-Med is a medtech company developing interventional cardiovascular devices, including a domestic fractional flow reserve (FFR) system approved by China's NMPA and an intravascular ultrasound (IVUS) system for precision diagnosis and treatment of cardiovascular diseases.
HealthtechMedical DevicesShenzhen, CN
Co-investorsHongShan Capital GroupQiming Venture Partners
Invitae provides genetic testing services to patients and clinicians across the United States, offering broad test offerings and genetic counseling to inform health decisions at every stage of life.
BiotechDigital HealthHealthtechMedical DevicesSan Francisco, US
Sean George(Executive Officer, Director)inRandal Scott(Executive Officer, Director)Shelly Guyer(Executive Officer)inLee Bendekgey(Executive Officer)inGeoffrey Crouse(Director)
BoardEric Aguiar(Director)in
Co-investorsCivilization Ventures Management, LlcFifty YearsManta Ray VenturesOberland CapitalPrefix CapitalTech Wildcatters+1 more
A biopharmaceutical company developing targeted cancer drugs and related therapies.
BiotechHealthtechMedical DevicesShanghai, CN
Co-investorsQiming Venture PartnersLilly Asia Ventures
LevitasBio develops label-free cell isolation and analysis technology for life science researchers, enabling higher-quality cell sample preparation without introducing bias or gene expression modifications.
BiotechDeep TechHardwareMedical Devices
Dr. Gozde Durmus(Co-founder)Dr. Utkan Demirci(Co-founder)Dr. Lars Steinmetz(Co-founder)
Co-investorsNovalis LifeSciences
Mammoth Bio develops technology to read and write the code of life, operating in the biotechnology sector.
BiotechDeep TechMedical DevicesBrisbane, US
Jennifer Doudna(Founder)inTrevor Martin(Co-founder, Chief Executive Officer)inJanice Chen(Co-founder, Chief Scientific Officer & President, Research)inLucas Harrington(Co-founder)inAshley Tehranchi(Executive Officer, Director)in
BoardUrshit Parikh(Director)
Co-investors8VCBerkeley FrontierCALIFORNIA INNOVATIONForesite CapitalMayfield FundMission Bay Capital+9 more
Xtremity makes the XtremityTT, a thermoformable definitive prosthetic socket system built from an injection-molded, carbon-reinforced polymer preform that clinicians can heat, form, and assemble in about an hour and re-adjust via spot-heating.
HardwareHealthtechMedical DevicesNew MaterialsAspen, US
Mark Joseph(Founder / Inventor & Product Designer)Miguelangel Sosa(Executive Officer, Director)Amy Hill(Executive Officer)Scott Ward(Executive Officer)
Co-investorsARCH Venture PartnersRsquared
Mirvie develops an RNA-based platform for early detection of pregnancy complications, enabling proactive intervention before complications become critical.
BiotechFemTechHealthtechSouth San Francisco, US
Maneesh Jain(Executive Officer, Director, Promoter)inStephen Quake(Director)
BoardLisa Iverson(Director)Ursheet Parikh(Director)inMin Cui(Director)inSamir Kaul(Director)in
Co-investorsMayfield FundPortfoliaBlackRockForesite CapitalGeneral CatalystGV (Google Ventures)+1 more
.png)
Nalu Medical develops a non-integrated neurostimulation system that uses electrical impulses to interrupt pain signals for patients with intractable chronic nerve pain.
HardwareHealthtechMedical DevicesCarlsbad, US
Earl Fender(President & CEO)inLee Hartley(Executive Officer)inAllen Meacham(Executive Officer)inBick Sellers(Executive Officer)inThomas A. West(Executive Officer, Director)inJeffrey Swiecki(Executive Officer)
Co-investorsAPERTURE Venture PartnersB Capital GroupB4 CapitalEndeavour VisionLongitude CapitalRunway Growth Capital+1 more
San Diego DNA sequencing company behind the Sequencing by Binding short-read platform; acquired by Pacific Biosciences in 2021.
BiotechSan Diego, US
David S. Mullarkey(Executive Officer, Director)Arnold Oliphant(Executive Officer)inKen Song, M.D., Ph.D.(Executive Officer, Director)Kelly Perez(Executive Officer)John Murphy, Ph.D.(Executive Officer)Millard Y Chan(Chief Operating Officer, Secretary and Director)
Co-investorsARCH Venture PartnersDCVC (Data Collective)ALTITUDE LIFE SCIENCE VENTURESDomain AssociatesHillhouse CapitalNan Fung Life Sciences
PackGene is a global Contract Research and Manufacturing Organization (CRO/CDMO) that produces gene therapy vectors and nucleic acid therapeutics for biopharmaceutical companies and research institutions, offering services from development through GMP-grade manufacturing.
Advanced ManufacturingBiotechDeep TechHealthtechMedical DevicesHouston, US
Co-investorsCathay Innovation
Polares Medical is a medical device company developing a device for treating mitral valve regurgitation.
HealthtechMedical DevicesPalo Alto, US
Alex Khairkhahan(Founder)in
Co-investorsLongitude CapitalEarlybird Venture CapitalEndeavour VisionIDO Investments
Readcoor developed an in situ spatial transcriptomics platform using padlock probe rolling circle amplification chemistry to detect and map RNA transcripts across tissue sections, now offered as the Xenium In Situ platform.
BiotechDeep TechHardwareHealthtechCambridge, US
Evan Daugharthy(Cofounder)Richard Terry(Executive Officer, Director)
BoardYuh-Geng Tsay(Director)Victor Tong(Director)Thomas Grogan(Director)
Co-investorsLAVLilly Asia VenturesLilly VenturesVivo Capital
Remix is a platform for public transit agencies to plan, schedule, and visualize transit systems in real-time.
GovTechLogistics & Supply ChainSaaSSan Francisco, US
Tiffany Chu(CEO & Cofounder)inSam Hashemi(Founder/CEO)inDaniel Getelman(Founder/CTO)inDanny Whalen(Founder)in
Co-investorsDesigner FundEnergy Impact PartnersY CombinatorSequoia Capital
.jpeg){kind=logo}
Remix is a mobile app that allows users to remix videos by pasting video links, adding photos, and instructing the app to make edits.
ConsumerCreator EconomySan Francisco, US
Sam Kaplan(Founder)in
Co-investorsCorazon CapitalY CombinatorEnergy Impact PartnersSequoia Capital
Remix provides an AI-powered management system that uses existing camera infrastructure to detect operational issues like long lines and inventory problems in real-time, then automatically routes fixes to staff with clear instructions and video evidence.
AI & Machine LearningEnterprise SoftwareFuture of WorkRetail TechPleasant Hill, US
Brandon Yowakim(Founder)inHenry Palmer(Founder)in
Co-investorsTechstarsEnergy Impact PartnersSequoia Capital
Remix Therapeutics develops RNA reprogramming technology to treat various diseases and disorders.
AI & Machine LearningBiotechWatertown, US
Peter Smith, PhD(Co-Founder, President and Chief Executive Officer)Peter Smith(Co-Founder, President and Chief Executive Officer)inRobert Gagnon(Executive Officer)Heather Wasserman(Executive Officer)inMatthew Patterson(Director)inScott Biller(Director)in
Co-investorsAtlas VentureForesite CapitalThe Column GroupARCH Venture Partners
ShapeTX develops programmable RNA medicines by combining artificial intelligence with RNA technology to address genetic causes of disease.
AI & Machine LearningBiotechDeep Tech
Josef von Rickenbach, PhD(Co-Founder)in
Co-investorsNew Enterprise Associates (NEA)Mission Biocapital
Take2 Health provides early cancer detection and screening services leveraging advanced technology and medical expertise to help individuals identify cancer at early stages.
BiotechDigital HealthHealthtechMedical DevicesHong Kong, HK
Terns Pharmaceuticals is a biopharmaceutical company developing therapies, including its TERN-701 program.
BiotechHealthtechFoster City, US
Mark Vignola, Ph.D.(Executive Officer)Bryan Yoon(Executive Officer)inSenthil Sundaram(Director, Executive Officer)inWeidong Zhong, Ph.D.(Executive Officer, Director)Jill Quigley(Director)inDavid Fellows(Director)
Co-investorsLAVLilly Asia VenturesVivo Capital
Vivo offers live, small-group fitness classes led by certified trainers over Zoom, combining strength training with cognitive exercises for older adults who work out from home.
Digital HealthHealthtechHR TechLongevityWellness & FitnessAtlanta, US
Eric(Founder, CEO)
BoardKendric Speagle(Director)
Co-investorsFlare Capital PartnersTechstars
Watchmaker Genomics develops and manufactures purpose-designed enzymes, reagents, and workflows for molecular biology and genomics applications, including inherited disease, somatic oncology, transcriptomics, and epigenomics research.
BiotechDeep TechHealthtechMedical DevicesBoulder, US
John Foskett(Executive Officer, Director, Promoter)Brian Deneau(Chief Operating and Finance Officer)inStephen Picone(Chief Strategic Officer)inBrian Kudlow(Chief Scientific Officer)inTrey Foskett(Chief Executive Officer)inKerri Stellato(Chief Commercial Officer)in
Co-investorsEclipse Ventures
YolTech Therapeutics develops in vivo gene editing medicines using a proprietary lipid nanoparticle delivery platform to treat genetic, metabolic, and autoimmune diseases.
AI & Machine LearningBiotechDeep TechHealthtechMedical Devices
Dr. Yuxuan Wu(Co-founder & CEO)
Zentalis is a biopharmaceutical company developing azenosertib and other pipeline assets, seeking strategic partnerships to advance drug development and expand market reach globally.
BiotechHealthtechMedical Devices
Julie Eastland(Chief Executive Officer and Director)in
BoardScott Myers(Chairperson)
Co-investorsHighlight Capital
Other
Tracked investments with no reachable website or further public details — typically companies that wound down, renamed, or were absorbed.
Baylor Genetics HoldingsHarton, Inc.ImmPACT Bio USA Inc.LevitasSunnyBay BioTech, Inc.10X Genomics-acquired company3SbioAccuragenAdapt PharmaApexigenAtriCure-acquired companyAytu BioscienceBecton Dickinson-acquired companyBYSICentricity VisionCollapsin Response Mediator Protein 2ConjugateBioEli Lilly-acquired companyEQEquillium BioEverest MedicinesFirefly Bio, Inc.GeneWeave BiosciencesGRAIL-acquired companyIllumina-acquired companyImmPACT BioIMPACT TherapeuticsIpsen-acquired companyKind PharmaceuticalsLuokungLuokung TechnologyMerck-acquired companyPacific Biosciences-acquired companyRegeneron-acquired companyRoche-acquired companyRucaparib (RCUS)SCYXShanghai Legend MedicalSINO Medical Sciences TechnologySolarionTern PharmaceuticalsUSCI Medical LaboratoryVertex-acquired companyZogenix
Rows marked “SEC filing” are inferred from directors named on the company's SEC Form D — public regulatory data, not a portfolio list published by the firm.
Exits · 13
9 IPOs · 4 acquisitions · showing 11Aardvark TherapeuticsNASDAQ: AARDGRAILNASDAQ: GRALAadi BioscienceNASDAQ: WHWKAdaptive BiotechnologiesNASDAQ: ADPTCG OncologyNASDAQ: CGONHealth CatalystNASDAQ: HCATNuvation BioNYSE: NUVBScynexisNASDAQ: SCYXUpstream BioNASDAQ: UPBAcelyrinacq. by AlumisHumiacq. by Employment Hero
Portfolio news
latest coverage across their companies
Nuvation Bio · aromatherapynaturals.com · Aug 22, 2026
Adaptive Biotechnologies · barchart.com · Aug 21, 2026
Firefly · siliconangle.com · Aug 20, 2026
Terns Pharmaceuticals · tradingkey.com · Aug 20, 2026
Arcus Biosciences · pluang.com · Aug 19, 2026
IPO stake values · per SEC filings · 3
Value of this firm's stake in each portfolio company at its IPO price, from the prospectus principal-stockholder table.
| Company | Owned | IPO price | At IPO | Stake value |
|---|---|---|---|---|
| CG Oncology | 6.1% | $28.00 | Dec 2024 | $127.6M |
| Upstream Bio | 6.0% | $17.00 | Oct 2024 | $52.4M |
| Aardvark Therapeutics | 12.5% | $16.00 | Feb 2025 | $42.7M |
Source: SEC S-1 / 424B prospectus filings. Stake value = shares beneficially owned × the initial public offering price, as disclosed — a market value at IPO, not a return multiple (the firm's original cost is not disclosed).
Public market activity · per SEC filings
what is this? ⓘDisclosed stake · filed Apr 2024
Disclosed stake · filed Feb 2021
5 insider ownership filings (Forms 3/4/5)
at Aardvark Therapeutics, Inc. (AARD), CG Oncology, Inc. (CGON)
From the firm's own SEC EDGAR filings — stakes and insider roles in public companies, typically portfolio companies after an IPO. Not a portfolio list published by the firm.
Frequently asked questions
- How many investments has Decheng Capital made?
- Decheng Capital has 103 tracked investments, 13 of which have exited, including 4 dated in the last 24 months.
- What stage does Decheng Capital invest at?
- Decheng Capital invests at the Seed, Series A, Growth stages.
- What sectors does Decheng Capital focus on?
- Decheng Capital focuses on Biotech, Digital Health, Healthtech, Medical Devices.
- Where is Decheng Capital located?
- Decheng Capital is headquartered in Menlo Park, US.
- Does Decheng Capital lead rounds?
- Decheng Capital typically participates in rounds rather than leading them.
- Who does Decheng Capital co-invest with?
- Decheng Capital most often shares deals with Foresite Capital, LAV, Lilly Asia Ventures, among 92 tracked co-investors.
Similar investors
Amadeus Capital Partners is a technology investment firm that backs founders building complex, science-led and deep tech businesses, supporting them over the long term as they scale internationally.
B Capital is a global investment firm backing early to late-stage technology innovators across technology, healthcare, and energy & resilience sectors.
Breyer Capital is a venture capital firm that backs high-impact entrepreneurs, making strategic investments guided by founder passion and its network of experienced investors.
Capricorn Partners is a Belgium-based, partner-owned independent management company for alternative investment funds, investing in innovative companies across digital, health and clean technologies with an ESG focus.
US Venture Partners (USVP) is an early-stage venture capital firm investing in information technology and healthcare companies, with four decades of investing experience.